Biography

Carlos L.  Arteaga, M.D., was appointed Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center in September 2017. He holds the Lisa K. Simmons Distinguished Chair in Comprehensive Oncology and brings translational research and cancer center leadership experience to the Simmons Cancer Center.

He earned his medical degree at the University of Guayaquil in Ecuador and trained in internal medicine and medical oncology at Emory University and the University of Texas Health Science Center San Antonio, respectively. He joined Vanderbilt University in 1989, where he held the Donna S. Hall Chair in Breast Cancer Research and served as Director of the Center for Cancer Targeted Therapies, Director of the Breast Cancer Program, and Associate Director for Translational/Clinical Research at the Vanderbilt-Ingram Cancer Center prior to UT Southwestern.

Dr. Arteaga is an internationally recognized expert in breast cancer with more than 350 publications in the areas of oncogenes and breast tumor initiation and progression, targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer. His research is or has been continuously funded by the National Cancer Institute, American Cancer Society (ACS), Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C), Susan G. Komen and Breast Cancer Research foundations, Cancer Prevention Research Institute of Texas, and industry.

His contributions have been published in Nature Medicine, Cancer Cell, Cancer DiscoveryScience Translational MedicineJournal of Clinical OncologyCell Metabolism, Journal of Clinical Investigation, Proceeding of the National Academy of Sciences of the United States of American, and Journal of the National Cancer Institute. 

During his career, he has received several awards, including the American Association for Cancer Research (AACR) Richard & Hinda Rosenthal Award, the ACS Clinical Research Professor Award (2007-2017), the Gianni Bonadonna Award from the American Society of Clinical Oncology (2009), the Brinker Award from the Susan G. Komen Foundation (2011), the Prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation (2015), and the Clinical Investigator Award from the Department of Veteran Affairs. 

Dr. Arteaga is a Fellow of the American Association for the Advancement of Science (2013) and Fellow of the AACR Academy (2015). He is an elected member of the American Society for Clinical Investigation (1998) and the Association of American Physicians (2005). He served on the NCI Board of Scientific Counselors (1999-2004) and NCI Subcommittee A (2004-2008).

Dr. Arteaga also serves on the advisory boards of several academic breast cancer programs, SU2C, Susan G. Komen Foundation, and five NCI-designated cancer centers. Since 2009, he has co-chaired the San Antonio Breast Cancer Symposium. In 2019, he was elected to serve on the Board of Directors of the American Association of Cancer Institutes (AACI). He was elected and served as the 2014-15 President of AACR, the largest cancer research organization in the world.

Education

Medical School
Universidad de Guayaquil, Ecuador (1980)
Residency
Emory University School of Medicine (1984), Internal Medicine
Fellowship
University of Texas Health Science Center, San Antonio (1988), Hematology Oncology

Publications

Featured Publications LegendFeatured Publications

ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors.
Guerrero-Zotano A, Stricker T, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Pérez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, Andre F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL Clin. Cancer Res. 2018 Mar
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB Nature 2018 Feb 554 7691 189-194
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, Sanders ME, Cook RS, Arteaga CL, Johnson DB, Balko JM Oncoimmunology 2018 7 6 e1438106
PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence and are exquisitely sensitive to PI3Ka inhibitors.
Croessmann S, Sheehan JH, Lee KM, Sliwoski GR, He J, Nagy RJ, Riddle DA, Mayer IA, Balko JM, Lanman RB, Miller V, Cantley LC, Meiler J, Arteaga CL Clin. Cancer Res. 2017 Dec
Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.
Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RS Target Oncol 2017 Dec
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL J. Natl. Cancer Inst. 2017 Nov 109 11
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
O'Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, Hart LL, Villanueva C, Jakobsen E, Beck JT, Lindquist D, Souami F, Mondal S, Germa C, Hortobagyi GN Breast Cancer Res. Treat. 2017 Nov
The Attenuation Distribution Across the Long Axis of Breast Cancer Liver Metastases at CT: A Quantitative Biomarker for Predicting Overall Survival.
Abramson RG, Lakomkin N, Hainline A, Kang H, Hutson MS, Arteaga CL AJR Am J Roentgenol 2017 Oct W1-W7
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.
Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, Nixon MJ, Estrada MV, Sánchez V, Sanders ME, Lee T, Gómez H, Lluch A, Pérez-Fidalgo JA, Wolf MM, Andrejeva G, Rathmell JC, Fesik SW, Arteaga CL Cell Metab. 2017 Oct 26 4 633-647.e7
Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors.
Limoge M, Safina A, Truskinovsky AM, Aljahdali I, Zonneville J, Gruevski A, Arteaga CL, Bakin AV Oncotarget 2017 Sep 8 37 61969-61981